Shaanxi Panlong Pharmaceutical Group Limited By Share Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 4/6
Shaanxi Panlong Pharmaceutical Group Limited By Share has been growing earnings at an average annual rate of 10.8%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 11.6% per year. Shaanxi Panlong Pharmaceutical Group Limited By Share's return on equity is 7.2%, and it has net margins of 11.8%.
Wichtige Informationen
10.8%
Wachstumsrate der Gewinne
7.6%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 10.9% |
| Wachstumsrate der Einnahmen | 11.6% |
| Eigenkapitalrendite | 7.2% |
| Netto-Marge | 11.8% |
| Letzte Ertragsaktualisierung | 30 Sep 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
There Is A Reason Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd's (SZSE:002864) Price Is Undemanding
Sep 30
Shaanxi Panlong Pharmaceutical Group Limited By Share's (SZSE:002864) Shareholders Will Receive A Bigger Dividend Than Last Year
May 31We Think That There Are Some Issues For Shaanxi Panlong Pharmaceutical Group Limited By Share (SZSE:002864) Beyond Its Promising Earnings
May 02Earnings Not Telling The Story For Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (SZSE:002864) After Shares Rise 32%
Mar 06Aufschlüsselung der Einnahmen und Ausgaben
Wie Shaanxi Panlong Pharmaceutical Group Limited By Share Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Sep 24 | 982 | 116 | 448 | 28 |
| 30 Jun 24 | 936 | 116 | 436 | 24 |
| 31 Mar 24 | 965 | 120 | 439 | 21 |
| 31 Dec 23 | 981 | 110 | 423 | 20 |
| 30 Sep 23 | 997 | 107 | 442 | 25 |
| 30 Jun 23 | 1,043 | 111 | 451 | 25 |
| 31 Mar 23 | 1,001 | 103 | 425 | 19 |
| 01 Jan 23 | 974 | 101 | 424 | 18 |
| 30 Sep 22 | 958 | 98 | 404 | 17 |
| 30 Jun 22 | 917 | 96 | 388 | 15 |
| 31 Mar 22 | 911 | 96 | 399 | 14 |
| 01 Jan 22 | 887 | 93 | 391 | 14 |
| 30 Sep 21 | 842 | 86 | 388 | 14 |
| 30 Jun 21 | 834 | 89 | 377 | 13 |
| 31 Mar 21 | 764 | 87 | 348 | 13 |
| 31 Dec 20 | 670 | 79 | 309 | 13 |
| 30 Sep 20 | 626 | 80 | 296 | 12 |
| 30 Jun 20 | 565 | 66 | 291 | 13 |
| 31 Mar 20 | 571 | 70 | 298 | 13 |
| 31 Dec 19 | 611 | 72 | 326 | 13 |
| 30 Sep 19 | 587 | 76 | 321 | 8 |
| 30 Jun 19 | 564 | 72 | 307 | 10 |
| 31 Mar 19 | 516 | 67 | 295 | 9 |
| 31 Dec 18 | 489 | 65 | 279 | 8 |
| 30 Sep 18 | 442 | 57 | 249 | 9 |
| 30 Jun 18 | 424 | 56 | 234 | 9 |
| 31 Mar 18 | 404 | 46 | 216 | 8 |
| 31 Dec 17 | 377 | 44 | 200 | 7 |
| 30 Sep 17 | 369 | 49 | 182 | 4 |
| 30 Jun 17 | 333 | 44 | 165 | 0 |
| 31 Mar 17 | 305 | 40 | 147 | 0 |
| 31 Dec 16 | 305 | 40 | 143 | 0 |
| 31 Dec 15 | 256 | 43 | 114 | 0 |
| 31 Dec 14 | 246 | 40 | 124 | 0 |
| 31 Dec 13 | 227 | 33 | 118 | 0 |
Qualität der Erträge: 002864 has high quality earnings.
Wachsende Gewinnspanne: 002864's current net profit margins (11.8%) are higher than last year (10.8%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 002864's earnings have grown by 10.8% per year over the past 5 years.
Beschleunigtes Wachstum: 002864's earnings growth over the past year (8%) is below its 5-year average (10.8% per year).
Erträge im Vergleich zur Industrie: 002864 earnings growth over the past year (8%) exceeded the Pharmaceuticals industry -1.2%.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 002864's Return on Equity (7.2%) is considered low.